Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. More Details
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Dynavax Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DVAX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: DVAX's weekly volatility has decreased from 15% to 9% over the past year.
7 Day Return
1 Year Return
Return vs Industry: DVAX underperformed the US Biotechs industry which returned 23.6% over the past year.
Return vs Market: DVAX underperformed the US Market which returned 39.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Dynavax Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StDynavax Technologies'(NASDAQ:DVAX) Share Price Is Down 39% Over The Past Five Years.
1 month ago | Simply Wall StIs Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
2 months ago | Simply Wall StNeed To Know: Analysts Are Much More Bullish On Dynavax Technologies Corporation (NASDAQ:DVAX) Revenues
Is Dynavax Technologies undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DVAX ($9.47) is trading below our estimate of fair value ($15.09)
Significantly Below Fair Value: DVAX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DVAX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: DVAX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DVAX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DVAX is overvalued based on its PB Ratio (10.9x) compared to the US Biotechs industry average (2.9x).
How is Dynavax Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DVAX's earnings are forecast to decline over the next 3 years (-5% per year).
Earnings vs Market: DVAX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: DVAX's is expected to become profitable in the next 3 years.
Revenue vs Market: DVAX's revenue (0.9% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: DVAX's revenue (0.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DVAX's Return on Equity is forecast to be high in 3 years time
How has Dynavax Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DVAX is currently unprofitable.
Growing Profit Margin: DVAX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DVAX is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.
Accelerating Growth: Unable to compare DVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: DVAX has a negative Return on Equity (-61.9%), as it is currently unprofitable.
How is Dynavax Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: DVAX's short term assets ($427.5M) exceed its short term liabilities ($109.4M).
Long Term Liabilities: DVAX's short term assets ($427.5M) exceed its long term liabilities ($280.9M).
Debt to Equity History and Analysis
Debt Level: DVAX's debt to equity ratio (180.3%) is considered high.
Reducing Debt: Insufficient data to determine if DVAX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DVAX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if DVAX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Dynavax Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DVAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DVAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DVAX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DVAX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DVAX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ryan Spencer (43 yo)
Mr. Ryan Spencer serves as the Chief Executive Officer and Director of Dynavax Technologies Corp. since December 16, 2019. He had been Co-President and Co-Principal Executive Officer of Dynavax Technologie...
CEO Compensation Analysis
Compensation vs Market: Ryan's total compensation ($USD1.52M) is below average for companies of similar size in the US market ($USD2.44M).
Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.
Experienced Management: DVAX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: DVAX's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.
Dynavax Technologies Corporation's company bio, employee growth, exchange listings and data sources
- Name: Dynavax Technologies Corporation
- Ticker: DVAX
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.085b
- Shares outstanding: 114.59m
- Website: https://www.dynavax.com
Number of Employees
- Dynavax Technologies Corporation
- 2100 Powell Street
- Suite 900
- United States
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for preve...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/25 22:36|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.